Protara confirms no material SVB exposure; cash runway into 2025 unchanged

Protara Therapeutics, Inc.

$102.3M cash equivalents invested in short-term treasury/corporate bonds, not SVB.
Operating account at SVB used only for monthly expenses; minimal balance.
Company does not expect SVB failure to impact operations or liquidity.
Reiterates cash runway guidance into 2025.

item 7.01

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-019281

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.